Topic: Ortho-Mcneil Inc.
ARNA) announced today that, following the completion of a Phase 1 clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminating the collaboration, effective ...
Johnson & Johnson (JNJ) subsidiary Ortho-McNeil-Janssen has tied up new diabetes drug development deals with Diamyd and Metabolex worth a potential $1 billion combined, adding therapies for both Type 1 and Type 2 diabetes to its pipeline. Hayward, California-based Metabolex will receive ...
J&J licenses late-stage Type 2 diabetes drug from Diamyd; gets preclincal drugs from MetabolexA unit of Johnson & Johnson has partnered with a Nordic pharmaceutical to develop a potential treatment for Type 1 diabetes, the company said Monday.Sweeden's Diamyd Medical AB is ...
